MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024. In this segment, Dr. Morrison introduces the concept of ...

A person receives subcutaneous immunotherapy as an injection under the skin. This treatment method has shown similar effectiveness to intravenous (IV) infusions that healthcare professionals often use ...

Engage: A Survivorship Program to Improve Childhood Cancer Survivors' Self-Efficacy and Quality of Life The development of subcutaneous (SC) formulations for monoclonal antibodies (mAbs), as an ...

Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...

TG Therapeutics, Inc.'s Phase 1 results of subcutaneous Briumvi are a major de-risking event. Click here to read more about ...

Medicare covers intravenous (IV) infusion therapy when a doctor prescribes it as medically necessary. Original Medicare Part A typically covers the costs if you have an IV infusion during an inpatient ...

TG Therapeutics stock popped Wednesday after the biotech company said an under-the-skin shot of Briumvi appeared as safe as the IV.